NIH-Sponsored Cardioprotection Consortium
CAESAR is a unique consortium formed to provide rigorous, preclinical testing of cardioprotective therapies and to facilitate the translation of promising therapies to the clinical arena. The CAESAR infrastructure is designed to identify therapies that are reproducibly effective and that have the highest probability of success in limiting infarct size in humans.
As a program funded by the National Heart, Lung and Blood Institute (NHLBI), CAESAR is a public resource open to the entire scientific community, including investigators in academia and the biomedical and pharmaceutical industries. Studies are selected based on scientific merit and potential for clinical application.